IMpower010: Exploratory analysis of disease-free survival by KRAS status in patients with stage II-IIIA NSCLC treated with adjuvant atezolizumab vs best supportive care

被引：0

作者：

Reck, Martin

Srivastava, Minu K.

Wakelee, Heather A.

Felip, Enriqueta

Altorki, Nasser K.

Csoszi, Tibor

Moiseyenko, Vladimir

Akopov, Andrey

Smolin, Alexey

Chella, Antonio

Vallieres, Eric

Martinez-Marti, Alex

Zou, Wei

McNally, V.

Bennett, Elizabeth

Prizant, Hen

Nabet, Barzin

Ballinger, Marcus

Gitlitz, Barbara J.

Zhou, Caicun

机构：

[1] German Ctr Lung Res, Lung Clin Grosshansdorf, Airway Res Ctr North, Grosshansdorf, Germany

[2] Genentech Inc, San Francisco, CA USA

[3] Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA USA

[4] Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Barcelona, Spain

[5] Weill Cornell Med, New York Presbyterian Hosp, New York, NY USA

[6] Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz R, Szolnok, Hungary

[7] GBUZ St Petersburg Clin Res Ctr Specialized Types, St Petersburg, Russia

[8] Pavlov State Med Univ, St Petersburg, Russia

[9] Principal Mil Clin Hosp NA NN Burdenko, Moscow, Russia

[10] Azienda Osped Univ Pisana, Pneumol Unit, Pisa, Italy

[11] Swedish Canc Inst, Seattle, WA USA

[12] Genentech Inc, San Francisco, CA USA

[13] Roche Prod Ltd, Welwyn Garden City, Herts, England

[14] Genentech Inc, S San Fransico, CA USA

[15] Tongji Univ, Shanghai Pulm Hosp, Shanghai, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8522

引用

页数：1

共 25 条

[1] IMpower010: Exploratory Analysis of Tumour Mutational Burden and Disease-Free Survival with Adjuvant Atezolizumab in NSCLC
Felip, E.
Srivastava, M.
Reck, M.
Wakelee, H.
Altorki, N.
Vallieres, E.
Liersch, R.
Oizumi, S.
Tanaka, H.
Hamm, J. T.
Novello, S.
McCune, S.
Molinero, L.
McNally, V.
Morris, S.
Ballinger, M.
Li, H.
Zou, W.
Nabet, B. J.
Bennett, E.
Gitlitz, B. J.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S139 - S139
[2] IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC
Zhou, C.
Das Thakur, M.
Srivastava, M. K.
Zou, W.
Xu, H.
Ballinger, M.
Felip, E.
Wakelee, H.
Altorki, N. K.
Reck, M.
Liersch, R.
Kryzhanivska, A.
Harada, M.
Tanaka, H.
Hamm, J.
McCune, S.
McNally, V.
Bennett, E.
Gitlitz, B.
Novello, S.
ANNALS OF ONCOLOGY, 2021, 32 : S1374 - S1374
[3] IMpower010:Overall Survival Interim Analysis of a Phase III Study of Atezolizumab vs Best Supportive Care in Resected NSCLC
Wakelee, H.
Altorki, N.
Felip, E.
Vallieres, E.
Vynnychenko, I. O.
Akopov, A.
Martinez-Marti, A.
Chella, A.
Bondarenko, I.
Sugawara, S.
Fan, Y.
Kenmotsu, H.
Chen, Y. -M.
Deng, Y.
Wu, F.
McNally, V.
Bennett, E.
Gitlitz, B. J.
Zhou, C.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S2 - S2
[4] IMpower010: A Phase III Study of Atezolizumab vs Best Supportive Care Following Adjuvant Chemotherapy in Completely Resected NSCLC
Felip, E.
Wakelee, H.
Vallieres, E.
Zhou, C.
Zuo, Y.
Xia, F.
Sandler, A.
Altorki, N.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2398 - S2399
[5] IMpower010: Updated overall survival and safety results from Asian patients in a Phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA NSCLC
Wang, Jie
Fan, Yun
Fang, Jian
He, Jianxing
Liu, Yunpeng
Tao, Min
Altorki, Nasser
Felip, Enriqueta
Wakelee, Heather
Vallieres, Eric
Belleli, Rossella
McNally, Virginia
Bennett, Elizabeth
Gitlitz, Barbara J.
Zhou, Caicun
CANCER RESEARCH, 2024, 84 (07)
[6] Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study
Felip, E.
Altorki, N. K.
Zhou, C.
Vallieres, E.
Vynnychenko, I. O.
Akopov, A.
Martinez-Marti, A.
Chella, A.
Bondarenko, I.
Ursol, G.
Levchenko, E.
Kislov, N.
Liersch, R.
Belleli, R.
McNally, V. A.
Bennett, E.
Gitlitz, B. J.
Wakelee, H.
ANNALS OF ONCOLOGY, 2022, 33 : S71 - S71
[7] IMpower010 5-y Subgroup Analysis and Relapse Patterns: Phase 3 Study of Atezolizumab vs BSC in Stage II-IIIA NSCLC
Felip, E.
Wakelee, H. A.
Vallieres, E.
Martinez-Marti, A.
Goloborodko, O.
Zhou, C.
Rittmeyer, A.
Chella, A.
Reck, M.
Csoszi, T.
Bondarenko, I.
Kenmotsu, H.
Schutte, W.
Ding, B.
Zhu, Q.
Ballinger, M.
Bennett, E.
Gitlitz, B. J.
Altorki, N.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S8 - S9
[8] Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: sub-analysis from the pivotal phase III IMpower010 study
Felip, Enriqueta
Altorki, Nasser
Zhou, Caicun
Vallieres, Eric
Vynnychenko, Ihor
Akopov, Andrey
Martinez-Marti, Alex
Chella, Antonio
Bondarenko, Igor
Ursol, Grygorii
Levchenko, Evgeny
Kislov, Nikolay
Liersch, Ruediger
Belleli, Rossella
Mcnally, Virginia
Bennett, Elizabeth
Gitlitz, Barbara
Wakelee, Heather
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 146 - 147
[9] IMpower010: Exploratory analysis of disease-free survival (DFS) by TGFβ cancer-associated fibroblast (CAF) gene signature expression in patients (pts) with resected NSCLC treated with atezolizumab (atezo) or best supportive care (BSC)
Altorki, N. K.
Reck, M.
Wakelee, H.
Felip, E.
Vallieres, E.
Liersch, R.
Oizumi, S.
Tanaka, H.
Novello, S.
McCune, S.
Li, H.
Molinero, L.
Mueller, S.
Bennett, E.
Gitlitz, B. J.
McNally, V. A.
Ballinger, M.
Nabet, B.
Srivastava, M. K.
Zhou, C.
ANNALS OF ONCOLOGY, 2023, 34 : S732 - S733
[10] IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC
Felip, E.
Vallieres, E.
Zhou, C.
Wakelee, H.
Bondarenko, I.
Sakai, H.
Saito, H.
Ursol, G.
Kawaguchi, K.
Liu, Y.
Levchenko, E.
Kislov, N.
Reck, M.
Liersch, R.
McNally, V. A.
Zhu, Q.
Ding, B.
Bennett, E.
Gitlitz, B.
Altorki, N. K.
ANNALS OF ONCOLOGY, 2021, 32 : S1319 - S1319

← 1 2 3 →